within Pharmacolibrary.Drugs.ATC.N;

model N05CM07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.08 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Triclofos is a sedative and hypnotic drug, historically used as a sleep-inducing agent, particularly in pediatrics for sedation. It is a prodrug of trichloroethanol, which is the active metabolite responsible for its pharmacological effect. It is rarely used in contemporary medical practice and is largely replaced by safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for orally administered triclofos, assuming use in pediatric population based on typical clinical protocols. No primary literature reporting human PK values found.</p><h4>References</h4><ol><li><p>Saarnivaara, L, et al., &amp; Pihlajamäki, K (1985). Comparison of pharmacokinetic and pharmacodynamic parameters following oral or intramuscular atropine in children. Atropine overdose in two small children. <i>Acta anaesthesiologica Scandinavica</i> 29(5) 529–536. DOI:<a href=&quot;https://doi.org/10.1111/j.1399-6576.1985.tb02248.x&quot;>10.1111/j.1399-6576.1985.tb02248.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4036539/&quot;>https://pubmed.ncbi.nlm.nih.gov/4036539</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CM07;
